Clinical trials: Hepatic Tumors
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally…
- Trial name
- NCT05733598
- Testing
- RP2, Bevacizumab, Atezolizumab
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Replimune, Inc.
Advanced Hepatocellular Carcinoma (HCC)
A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
- Trial name
- NCT01101906
- Testing
- OSI-906
- Where
- 41 sites in United States, Belgium and 8 more
- Volunteers
- 23 people
- Sponsor
- Astellas Pharma Inc
Carcinoma, Hepatocellular
A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma
The primary purpose of this study is to further characterise the hepatotoxicity in participants with advanced or unresectable hepatocellular carcinoma (HCC) treated with lenvatinib, and to further characterise the overall safety…
- Trial name
- STELLAR (NCT04763408)
- Testing
- Lenvatinib, Sorafenib
- Where
- 44 sites in United States, Australia and 8 more
- Volunteers
- 335 people
- Sponsor
- Eisai Inc.
Primary Liver Cancer, Hepatocellular Carcinoma
Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors
- Conditions
- Primary Liver Cancer, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Combined Hepatocellular-cholangiocarcinoma
- Trial name
- NCT05292443
- Testing
- Observation
- Where
- 5 sites in China
- Sponsor
- Geneplus-Beijing Co. Ltd.
Hepatocellular Carcinoma
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
This is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
- Trial name
- TREMENDOUS-2 (NCT07081633)
- Testing
- Durvalumab, Tremelimumab, Lenvatinib
- Where
- 23 sites in China, Hong Kong
- Volunteers
- 114 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
- Trial name
- NCT00423306
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Alaunos Therapeutics
Hepatocellular Carcinoma
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
This study is an open phase II clinical study, which consists of part a and Part B. Part a will evaluate the safety and tolerability of absk-011 combined with atilizumab in patients with advanced or unresectable HCC to And pk/pd…
- Trial name
- NCT05441475
- Testing
- ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w, ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg, ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Metastatic Breast Cancer in the Liver
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
The goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with breast cancer that has spread to the liver is safe and…
- Trial name
- DELUMA (NCT06875128)
- Testing
- Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine), Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
- Where
- 8 sites in United States, Italy and 2 more
- Volunteers
- 90 people
- Sponsor
- Delcath Systems Inc.
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Liver Tumor, Hepatocellular Carcinoma
NeuWave Microwave Ablation HCC China Study
This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the…
- Trial name
- NW (NCT03783871)
- Testing
- Microwave ablation
- Where
- 4 sites in China
- Volunteers
- 135 people
- Sponsor
- Ethicon, Inc.
NSCLC, Prostate Cancer
Clinical Trial of TB511 in Advanced Solid Tumors
1. Study population [TB511 Monotherapy Cohort for Phase 1 and Phase 2a Clinical Trial] Patients with advanced solid tumors who are either refractory or intolerant to standard of care (SoC).
- Conditions
- NSCLC, Prostate Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06400160
- Testing
- TB511, Keytruda
- Volunteers
- 12 people
- Sponsor
- Twinpig Biolab, Inc.
Liver Cancer
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and to investigate the efficacy, safety and pharmacokinetics of irofulven combined with oxaliplatin in patients with advanced solid tumors.
- Trial name
- NCT00374660
- Testing
- Oxaliplatin, Irofulven
- Where
- 7 sites in France
- Volunteers
- 63 people
- Sponsor
- Eisai Inc.
Hepatocellular Carcinoma
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
- Trial name
- HCC (NCT04560894)
- Testing
- SCT-I10A, SCT510, Sorafenib 200mg
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Sinocelltech Ltd.
Hepatocellular Carcinoma
Safety and Efficacy of Degradable Microsphere in Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma
The purpose of this study was to prospectively collect clinical data from patients who underwent hepatic artery chemoembolization using microspheres with different degradation times (2 hours, 1 day, 2 weeks) based on standard…
- Trial name
- NCT05072041
- Testing
- Nexsphere™
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Next Biomedical Co., Ltd.
Cancer, Lung, Cancer, Breast
Early Detection of Five Common Cancers Using the ctDNA Analysing Test
This is a multi-centre, prospective cohort study, aiming to evaluate a blood test in early detection of the four common cancers, based on the investigation of the circulating tumour DNA (ctDNA).
- Conditions
- Cancer, Lung, Cancer, Breast, Cancer Liver, Cancer, Colorectal
- Trial name
- K-DETEK (NCT05227261)
- Where
- Vietnam
- Volunteers
- 9,057 people, healthy volunteers welcome
- Sponsor
- Gene Solutions
Hepatocellular Carcinoma
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Trial name
- NCT07813572
- Testing
- ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Unresectable Hepatocellular Carcinoma
First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)
This study looks at how a combination of two medicines, nivolumab and ipilimumab, is used to treat people with advanced liver cancer that cannot be removed by surgery.
- Trial name
- NCT07679061
- Testing
- Nivolumab plus ipilimumab
- Where
- 2 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
Head & Neck Cancer, Pancreas Carcinoma
SL-28 for Advanced Solid Tumours
Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours.
- Conditions
- Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma
- Trial name
- NCT07341737
- Testing
- SL-28
- Where
- 3 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Second Life Therapeutics
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer